

## DAFTAR PUSTAKA

- Adam, A. D. (2010). *Review of Oral Iron Chelators (Deferiprone and Deferasirox) for The Treatment of Iron Overload in Pediatric Patients*. Kansas: University of Missouri - Kansas City School of Medicine.
- Asti Y.R., Ajeng D., Keri Lestari. (2016). *Efficacy and Side Effect of Deferasirox and Deferiprone For Thalassemia Mayor in Children*. Bandung: Universitas Padjadjaran
- Berger, ML., Birgefors K., Hedblom E., Pashus CL., Torrance G. Smith MD. (2003). *Health Care Cost, Quality, and Outcomes*. USA: ISPOR.
- Bergeron RJ, Streiff RR, Wiegand J., Luchetta G., Creary EA, Peter HH. (1992). *Blood. A Comparison of The Iron Chelating Properties of 1,2-dimethyl-3-hydroxypyrid-4-one, 1,2-diethyl-3-hydroxypyrid-4-one, and Deferoxamine*.
- Bootman JL. (2005). *Principle of Pharmacoeconomics 3rd Edition*. USA: Harvey Whitney Books Company.
- Brent, R. (2003). *Cost Benefit Analysis and Health Care Evaluation*. UK: Edward Elgar Publishing.
- Brittenham GM, Griffith PM, Nienhuis AW, et al. (1994). *N Engl J Med. Efficacy of Deferoxamine in Preventing Complications of Iron Overload in Patients wit Thalassemia Major*.
- Capellini MD, Musallam KM, Taher AT. (2009). *Hemoglobin. Overview of Iron Chelation Therapy with Desferrioxamine and Deferiprone*.
- Cappellini MD, Cohen A, Piga A. (2006). *Blood. A Phase 3 Study of Deferasirox (ICL 670), a Once-daily Oral Iron Chelator, in Patients with B-thalassemia*.
- Cappellini MD, Porter J., El-Beshlawy A. (2010). *Haematologica. Tailoring Iron Chelation by Iron Intake and Serum Ferritin: The Prospective EPIC Study of Deferasirox in 1744 Patients with Transfusion-dependent Anemia*.
- Ceci A., Baiardi P., Felisi M. (2002). *Br J Haematol. The Safety and Effectiveness of Deferiprone in a Large-scale 3-year Study in Italian Patients*.
- Charlie A.G. (2017). *Analisis Efisiensi Biaya Obat Setelah Dilakukan Telaah Resep dan Intervensi Apoteker dalam Pelayanan Farmasi JKN Rawat Jalan di RS PKU Muhammadiyah Yogyakarta*. Yogyakarta

- Cohen AR, Galanello R., Piga A., De Sanctis V., Tricta F. (2003). Blood. *Safety and Effectiveness of Long-term Therapy with The Oral Iron Chelator Deferiprone.*
- Dewi S. (2009). Karakteristik Talasemia yang Dirawat Inap di RSUP Haji Adam Malik Medan. Medan.
- Didik S., Dwi E., dan Auliya A.S. 2017. *Farmakoekonomi Modeling.* Purwokerto: UMP Press
- Drummond MF, M.J. Sculpher, G.W. Torrance, DJ O'Brien, and Stoddart. (2005). *Methods for The Economic Evaluation of Health Care Programme 3rd Edition.* UK: Oxford University.
- El Alfy M., Sari TT, Lee CL, Tricta F., El-Beshlawy A. (2000). J Pediatr Hematol Oncol. *The Safety, Tolerability, and Efficacy of a Liquid Formulation of Deferiprone in Young Children with Transfusional Iron Overload.*
- Gibson R. (1993). *Nutritional Assesment a Laboratory Manual.* New York: Oxford university press
- Glickstein H., El RB, Link G. (2006). Blood. *Action of Chelators in Iron-loaded Cardiac Cells.*
- Goel H., Girish KM, Phadke SP. (2008). Hematology. *Long-term Efficacy of Oral Deferiprone in Management of Iron Overload in Beta Thalassemia Major.*
- Harvina Sawitri, Cut Asmaul Husna. (2018). Karakteristik Pasien Talasemia Mayor di BLUD RSU Cut Meutia Aceh Utara Tahun 2018. Aceh.
- Hana G.C., Rani S., dan Nanda A.R. (2018). *Cost-effectiveness Analysis of Deferiprone and Deferasirox on Thalassemia Major Patients in Tangerang District Hospital, Indonesia.* Jakarta.
- Hoffrand AV, P. J. (1996). *Kapita Selektta Hematologi.* Jakarta: EGC.
- <https://www.thalassemia.org/boduw/wp-content/uploads/2017/11/Thalassemia-Adoption-FAQs>, akses Tanggal 3 April 2021 18:26
- <https://pubchem.ncbi.nlm.nih.gov/>, akses Tanggal 3 Februari 2021 11:00
- <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dc8cbc3d-026c-0db5-42e8-8e93d374dd23>, *Hazardous Substances Data Bank*, akses Tanggal 3 Februari 2021 15:00
- Katzung Bertran G., B. Susan, Trevor Anthony J. (2016). *Clinical Pharmacology 12th Edition.* Jakarta: EGC.

- Katzung Betran G. (1998). *Basic and Clinical Pharmacology 6th Edition*. Jakarta: EGC.
- Kesehatan, K. (2018, Maret 5). *Pedoman Nasional Pelayanan Kedokteran Tata Laksana Talasemia*. Retrieved September 1, 2019, from [www.persi.or.id](http://www.persi.or.id): <https://www.persi.or.id/images/regulasi/kepmenkes/kmk12018.pdf>
- Kwiatkoswki JL. (2008). *Pediatr Clin N Am. Oral Iron Chelators*.
- Lindsey WT., Olin BR. (2007). *Clin Ther. Deferasirox for Transfusion-related Iron Overload: A Clinical Review*.
- Makroo RN. (1999). *Compendium of Ttransfusion Medicine*. New Delhi: J Mitra & Co.Utd
- Matsui D., e. a. (2010). Relationship Between The Pharmacokinetics and Iron Excretion Pharmacodynamics of The New Oral Iron Chelator 1,2-dimethyl-3-hydroxypyrid-4-one in Patients with Thalassemia. *Clinical Pharmacology*.
- Mc. Phee Stephen J., Genong William F. (2015). *Pathophysiology of Disease: An Introduction to Clinical Medicine*. Jakarta: Penerbit Buku Kedokteran EGC.
- Mc. Phee Stephen J., Papadalis Maxine A. (2007). *Current Medical Diagnosis & Treatment 47th Edition*. United States of america: Mc. Graw Hill Medical.
- Michele Woodley, Alison Welan. (1995). *Manual of Medical Therapeutics*. Yogyakarta: Yayasan Essentia Medica.
- Neufeld EJ. (2006). *Blood. Oral Chelators Deferasirox and Deferiprone for Transfusional Iron Overload in Thalassemia Major; New Data, New Questions*.
- Newby B., S.Hill. (2003). *Use of Pharmacoeconomies in Prescribing Research, Part 2: Cost Minimization Analysis- When are Two Tharapies Equal*. *Journal of Clinical Pharmacy and Terapeutics*.
- Nisbet-Brown E, Olieveri NF, Giardina PJ. (2003). *Lancet. Effectiveness and Safety of ICL670 in Iron-loaded Patients with Thalassemia: a Randomized, Double-blind, Placebo-controlled, Dose-escalation Trial*.
- Olieveri NF, Briettenham GM, Matsui D. (1995). *N Engl J Med. Iron Chelation Therapy with Oral Deferiprone in Patients with Thalassemia Major*.

- Oliveri NF, Brittenham GM, Mc Laren CE. (1998). *N engl J Med. Long-term Safety and Effectiveness of Iron-chelation Therapy with Deferiprone for Thalassemia Major.*
- Oliveri NF, Koren G., Hermann C. (1990). *Lancet. Comparison of Oral Iron Chelator LI and Deferrioxamine in Iron-loaded Patients.*
- Oliveri NF. (1999). *The Talasemia. N Engl J Med.;341: 99-107*
- Pennell DJ, Porter JB, Cappellini MD. (2010). *Blood. Efficacy of Deferasirox in Reducing and Preventing Cardiac Iron Overload in B-thalassemia.*
- Piga A, Roggero S., Salussolia I., Massano D., Sarra M., Longo F. (2010). *Deferiprone. New York: Acad Sci.*
- Rascati, K. e. (2009). *Essentials of Pharmacoeconomics. Philadelphia: Lippincott William & Wilkies.*
- Rian C. (2016). *Analisis Efektifitas Biaya Terapi Kelasi Besi Pada Pasien Talasemia di RSUD Dr. Zainoel Abidin Banda Aceh. Aceh.*
- Rund D, Rachmilewitz E. (2005). *Talasemia. N Engl J Med.*
- Sfeir HE. (2006). *Hemochromatosis. 2006 Nov 8 [cited 2007 Oct 30]; Available from: URL: <http://www.emedicine.com/MED/topic>*
- Sofro AS. (2002). *Cross Over in Talasemia. In: Proceeding book of 12<sup>th</sup> national congress of child health and 11<sup>th</sup> ASEAN pediatric federation conference; 2002 June 30- July 4; Bali, Indonesia. Bali: IDAI*
- Taher A., Cappellini MD, Vichinsky E. (2009). *Br J Haematol. Efficacy and Safety of Deferasirox Dose of > 30 mg/kg per d in Patients with Transfusion-dependent Anaemia and Iron Overload.*
- Taher A., El-Beshlawy A., Elalfy M. (2009). *Er J Haematol. Efficacy and Safety of Deferasirox, an Oral Iron Chelator, in Heavily Iron-Overloaded Patients with B-thalassemia: the ESCALATOR Study.*
- Thabrany Abdullah, Afdhal Ahmad Fuad, Thohari Jarir. (2013). *Pedoman Penerapan Kajian Farmakoekonomi. Jakarta: Kementerian Kesehatan.*
- Theil EC. (2003). *Ferritin: At The Crossroads of Iron and Oxygen Metabolism. J. Nutr 2003:1549-53.*
- Toy Eugene C., Patlam John T. (2007). *Case File Internal Medicine 4th Edition. United States of America: Mc. Graw Hill Company.*

- Tri Murti Andayani. (2013). *Farmakoekonomi Prinsip dan Metodologi*. Yogyakarta: Bursa Ilmu Yogyakarta
- Vichinsky E., Onyekwere O., Porter J. (2006). *Br J Haematol. A Randomized Comparison of Deferasirox versus Deferoxamine for the Treatment of Transfusional Iron Overload in Sickle Cell Disease.*
- Wahidiyat I. (2005). *Talasemia dan Permasalahannya di Indonesia*. Dalam: Firmansyah A, Sastroasmoro S, Trihono PD, Pujiadi A, Tridjaja B, Mulya GD, penyunting. Naskah Lengkap KONIKA XI; 4-7 Juli 1999; Jakarta: IDAI
- Wahidiyat I. (2005). *Masalah Medikopsikosial Talasemia di Masa Mendatang di Indonesia*. Dalam: Abdulsalam M, Windiastuti E, penyunting. Kumpulan naskah KONAS X PHTDI; 29-30 Mei 2005; Denpasar: IDAI
- Waldmeier F., Bruin GJ., Glaenzel U. (2010). *Drug Metab Dispos. Pharmacokinetics, Metabolism, and Disposition of Deferasirox in Beta-thalassemic Patients with Transfusion-dependent Iron Overload Who Are at Pharmacokinetics Steady State.*
- Wood JC, Otto-Duessel M., Gonzales. (2006). *Trans Res. Deferasirox and Deferiprone remove Cardiac Iron in Iron-overloaded Gerbil.*

